RCMI Coordinating Center (RCMI CC) Header Logo

Connection

Emmanuel Akala to Antineoplastic Agents

Back to Details
This is a "connection" page, showing publications Emmanuel Akala has written about Antineoplastic Agents.
Emmanuel Akala
Connection Strength
0.910
Antineoplastic Agents
  1. Mandala B, Berko Y, Battogtokh G, Fisusi F, Gao H, Akala EO. Nanotechnology Platform for the Delivery of Docetaxel and Tyrosine Kinase Inhibitors for HER2-Positive Breast Cancer Therapy. Pharm Nanotechnol. 2025; 13(5):1017-1043.
    View in: PubMed
    Score: 0.505
  2. Fisusi FA, Akala EO. Drug Combinations in Breast Cancer Therapy. Pharm Nanotechnol. 2019; 7(1):3-23.
    View in: PubMed
    Score: 0.333
  3. Puri R, Berhe SA, Akala EO. pH-Sensitive Polymeric Nanoparticles Fabricated by Dispersion Polymerization for the Delivery of Bioactive Agents. Pharm Nanotechnol. 2017; 5(1):44-66.
    View in: PubMed
    Score: 0.072
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
RCMI CC is supported by the National Institute on Minority Health and Health Disparities, National Institutes of Health (NIH), through Grant Number U24MD015970. The contents of this site are solely the responsibility of the authors and do not necessarily represent the official views of the NIH

For technical support please contact support